Q/C TECHNOLOGIES, INC. — Director's Dealing 2021

Apr 21, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MyMD Pharmaceuticals, Inc. (MYMD)
CIK: 0001321834
Period of Report: 2021-04-16

Reporting Person: Chapman Christopher C JR (Director, President, Chief Med. Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-16	Common Stock	A	96475	—	Acquired	96475	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-16	Stock Option (Right to Buy)	$2.5913	A	38590	Acquired	2023-04-16	Common Stock (38590)	Direct
2021-04-16	Stock Option (Right to Buy)	$2.5913	A	77180	Acquired	2023-04-16	Common Stock (77180)	Direct
2021-04-16	Stock Option (Right to Buy)	$2.5913	A	77180	Acquired	2023-04-16	Common Stock (77180)	Direct
2021-04-16	Stock Option (Right to Buy)	$2.5913	A	96475	Acquired	2023-04-16	Common Stock (96475)	Direct

Footnotes

F1: Received in exchange for 250,000 shares of common stock of a private company formerly known as "MyMD Pharmaceuticals, Inc." (the "Former Entity") in connection with the merger of the Former Entity with and into a wholly owned subsidiary of the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's common stock was $4.94 per share.

F2: Received in the Merger in exchange for a stock option to acquire 100,000 shares of common stock of the Former Entity at $1.00 per share.

F3: These options are fully vested and exercisable.

F4: Received in the Merger in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share.

F5: Received in the Merger in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share.

F6: Received in the Merger in exchange for a stock option to acquire 250,000 shares of common stock of the Former Entity at $1.00 per share.